Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
PaperCitations, authors & open-access status
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 339 citations, 2021 year and bronze oa status.
339
Citations
2021
Year
bronze
OA Status